MMPs as therapeutic targets—Still a viable option?

Matrix metalloproteinases (MMPs) appear to be ideal drug targets—they are disease-associated, extracellular enzymes with a dependence on zinc for activity. This apparently straightforward target, however, is much more complex than initially realized. Although disease associated, the roles for partic...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in cell & developmental biology 2008-02, Vol.19 (1), p.61-68
Main Author: Fingleton, Barbara
Format: Article
Language:English
Subjects:
Animal models
Animals
Clinical Trials as Topic
Drug Delivery Systems
Enzyme Inhibitors - therapeutic use
Humans
Inhibitors
Matrix Metalloproteinase Inhibitors
Matrix Metalloproteinases - physiology
Metabolic Diseases - drug therapy
Models, Animal
Side effects
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c527t-5c69c7bfade0dc74131bddb7e059ed3ecf3759d02d19604de5faf71a3f7866e73
cites
container_end_page 68
container_issue 1
container_start_page 61
container_title Seminars in cell & developmental biology
container_volume 19
creator Fingleton, Barbara
description Matrix metalloproteinases (MMPs) appear to be ideal drug targets—they are disease-associated, extracellular enzymes with a dependence on zinc for activity. This apparently straightforward target, however, is much more complex than initially realized. Although disease associated, the roles for particular enzymes may be healing rather than harmful making broad-spectrum inhibition unwise; targeting the catalytic zinc with specificity is difficult, since other related proteases as well as non-related proteins can be affected by some chelating groups. While the failure of early-generation MMP inhibitors dampened enthusiasm for this type of drug, there has recently been a wealth of studies examining the basic biology of MMPs which will greatly inform new drug trials in this field.
doi_str_mv 10.1016/j.semcdb.2007.06.006
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2677300</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1084952107000912</els_id><sourcerecordid>70154020</sourcerecordid><originalsourceid>FETCH-LOGICAL-c527t-5c69c7bfade0dc74131bddb7e059ed3ecf3759d02d19604de5faf71a3f7866e73</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EgvL4A4SyYpcwjh272YAQ4iW1AglYW449aV2lSbHdSuz4CL6QL6FVKx4bVjPS3Htn5hByTCGjQMXZJAs4NbbKcgCZgcgAxBbpUShFygTj26u-z9OyyOke2Q9hAgC8zMUu2aNSlIwC7xE-HD6GRIckjtHrGc6jM0nUfoQxfL5_PEXXNIlOFk5XDSbdLLquvTgkO7VuAh5t6gF5ubl-vrpLBw-391eXg9QUuYxpYURpZFVri2CN5JTRytpKIhQlWoamZrIoLeSWlgK4xaLWtaSa1bIvBEp2QM7XubN5NUVrsI1eN2rm3VT7N9Vpp_5OWjdWo26hciElA1gGnG4CfPc6xxDV1AWDTaNb7OZBSaAFh3wl5Guh8V0IHuvvJRTUCreaqDVutcKtQKgl7qXt5PeBP6YN358PcIlp4dCrYBy2Bq3zaKKynft_wxcfh5Tu</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70154020</pqid></control><display><type>article</type><title>MMPs as therapeutic targets—Still a viable option?</title><source>ScienceDirect Journals</source><creator>Fingleton, Barbara</creator><creatorcontrib>Fingleton, Barbara</creatorcontrib><description>Matrix metalloproteinases (MMPs) appear to be ideal drug targets—they are disease-associated, extracellular enzymes with a dependence on zinc for activity. This apparently straightforward target, however, is much more complex than initially realized. Although disease associated, the roles for particular enzymes may be healing rather than harmful making broad-spectrum inhibition unwise; targeting the catalytic zinc with specificity is difficult, since other related proteases as well as non-related proteins can be affected by some chelating groups. While the failure of early-generation MMP inhibitors dampened enthusiasm for this type of drug, there has recently been a wealth of studies examining the basic biology of MMPs which will greatly inform new drug trials in this field.</description><identifier>ISSN: 1084-9521</identifier><identifier>EISSN: 1096-3634</identifier><identifier>DOI: 10.1016/j.semcdb.2007.06.006</identifier><identifier>PMID: 17693104</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animal models ; Animals ; Clinical Trials as Topic ; Drug Delivery Systems ; Enzyme Inhibitors - therapeutic use ; Humans ; Inhibitors ; Matrix Metalloproteinase Inhibitors ; Matrix Metalloproteinases - physiology ; Metabolic Diseases - drug therapy ; Models, Animal ; Side effects ; Treatment Outcome</subject><ispartof>Seminars in cell &amp; developmental biology, 2008-02, Vol.19 (1), p.61-68</ispartof><rights>2007 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c527t-5c69c7bfade0dc74131bddb7e059ed3ecf3759d02d19604de5faf71a3f7866e73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17693104$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fingleton, Barbara</creatorcontrib><title>MMPs as therapeutic targets—Still a viable option?</title><title>Seminars in cell &amp; developmental biology</title><addtitle>Semin Cell Dev Biol</addtitle><description>Matrix metalloproteinases (MMPs) appear to be ideal drug targets—they are disease-associated, extracellular enzymes with a dependence on zinc for activity. This apparently straightforward target, however, is much more complex than initially realized. Although disease associated, the roles for particular enzymes may be healing rather than harmful making broad-spectrum inhibition unwise; targeting the catalytic zinc with specificity is difficult, since other related proteases as well as non-related proteins can be affected by some chelating groups. While the failure of early-generation MMP inhibitors dampened enthusiasm for this type of drug, there has recently been a wealth of studies examining the basic biology of MMPs which will greatly inform new drug trials in this field.</description><subject>Animal models</subject><subject>Animals</subject><subject>Clinical Trials as Topic</subject><subject>Drug Delivery Systems</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Humans</subject><subject>Inhibitors</subject><subject>Matrix Metalloproteinase Inhibitors</subject><subject>Matrix Metalloproteinases - physiology</subject><subject>Metabolic Diseases - drug therapy</subject><subject>Models, Animal</subject><subject>Side effects</subject><subject>Treatment Outcome</subject><issn>1084-9521</issn><issn>1096-3634</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOwzAQRS0EgvL4A4SyYpcwjh272YAQ4iW1AglYW449aV2lSbHdSuz4CL6QL6FVKx4bVjPS3Htn5hByTCGjQMXZJAs4NbbKcgCZgcgAxBbpUShFygTj26u-z9OyyOke2Q9hAgC8zMUu2aNSlIwC7xE-HD6GRIckjtHrGc6jM0nUfoQxfL5_PEXXNIlOFk5XDSbdLLquvTgkO7VuAh5t6gF5ubl-vrpLBw-391eXg9QUuYxpYURpZFVri2CN5JTRytpKIhQlWoamZrIoLeSWlgK4xaLWtaSa1bIvBEp2QM7XubN5NUVrsI1eN2rm3VT7N9Vpp_5OWjdWo26hciElA1gGnG4CfPc6xxDV1AWDTaNb7OZBSaAFh3wl5Guh8V0IHuvvJRTUCreaqDVutcKtQKgl7qXt5PeBP6YN358PcIlp4dCrYBy2Bq3zaKKynft_wxcfh5Tu</recordid><startdate>20080201</startdate><enddate>20080201</enddate><creator>Fingleton, Barbara</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20080201</creationdate><title>MMPs as therapeutic targets—Still a viable option?</title><author>Fingleton, Barbara</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c527t-5c69c7bfade0dc74131bddb7e059ed3ecf3759d02d19604de5faf71a3f7866e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Animal models</topic><topic>Animals</topic><topic>Clinical Trials as Topic</topic><topic>Drug Delivery Systems</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Humans</topic><topic>Inhibitors</topic><topic>Matrix Metalloproteinase Inhibitors</topic><topic>Matrix Metalloproteinases - physiology</topic><topic>Metabolic Diseases - drug therapy</topic><topic>Models, Animal</topic><topic>Side effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fingleton, Barbara</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Seminars in cell &amp; developmental biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fingleton, Barbara</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MMPs as therapeutic targets—Still a viable option?</atitle><jtitle>Seminars in cell &amp; developmental biology</jtitle><addtitle>Semin Cell Dev Biol</addtitle><date>2008-02-01</date><risdate>2008</risdate><volume>19</volume><issue>1</issue><spage>61</spage><epage>68</epage><pages>61-68</pages><issn>1084-9521</issn><eissn>1096-3634</eissn><abstract>Matrix metalloproteinases (MMPs) appear to be ideal drug targets—they are disease-associated, extracellular enzymes with a dependence on zinc for activity. This apparently straightforward target, however, is much more complex than initially realized. Although disease associated, the roles for particular enzymes may be healing rather than harmful making broad-spectrum inhibition unwise; targeting the catalytic zinc with specificity is difficult, since other related proteases as well as non-related proteins can be affected by some chelating groups. While the failure of early-generation MMP inhibitors dampened enthusiasm for this type of drug, there has recently been a wealth of studies examining the basic biology of MMPs which will greatly inform new drug trials in this field.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>17693104</pmid><doi>10.1016/j.semcdb.2007.06.006</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1084-9521
ispartof Seminars in cell & developmental biology, 2008-02, Vol.19 (1), p.61-68
issn 1084-9521
1096-3634
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2677300
source ScienceDirect Journals
subjects Animal models
Animals
Clinical Trials as Topic
Drug Delivery Systems
Enzyme Inhibitors - therapeutic use
Humans
Inhibitors
Matrix Metalloproteinase Inhibitors
Matrix Metalloproteinases - physiology
Metabolic Diseases - drug therapy
Models, Animal
Side effects
Treatment Outcome
title MMPs as therapeutic targets—Still a viable option?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T14%3A26%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MMPs%20as%20therapeutic%20targets%E2%80%94Still%20a%20viable%20option?&rft.jtitle=Seminars%20in%20cell%20&%20developmental%20biology&rft.au=Fingleton,%20Barbara&rft.date=2008-02-01&rft.volume=19&rft.issue=1&rft.spage=61&rft.epage=68&rft.pages=61-68&rft.issn=1084-9521&rft.eissn=1096-3634&rft_id=info:doi/10.1016/j.semcdb.2007.06.006&rft_dat=%3Cproquest_pubme%3E70154020%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c527t-5c69c7bfade0dc74131bddb7e059ed3ecf3759d02d19604de5faf71a3f7866e73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=70154020&rft_id=info:pmid/17693104&rfr_iscdi=true